secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scorpius Holdings, Inc. (—)
CIK:        0001476963
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001558370-23-004449
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NightHawk Biosciences restates Q2 and Q3 2022 financials; net loss overstated
-----------------------------------------------------------------------------

- Net loss overstated by ~$3.3M for Q2 2022 and ~$2.9-3.3M for Q3 2022 due to deferred tax asset valuation allowance error from Elusys acquisition.
- Restatement will decrease net loss per share by $0.13 for Q2 and $0.12-$0.13 for Q3.
- Material weakness identified in internal controls over income tax accounting; remediation plan to be described in 2022 10-K.
- Audit committee concluded prior period financials should no longer be relied upon.
- Errors had no effect on cash position, pre-tax loss, or operating expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1476963/000155837023004449/0001558370-23-004449-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1476963/000155837023004449/nhwk-20230317x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-004449

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer